206 related articles for article (PubMed ID: 25172803)
1. An analysis of FDA-approved drugs for oncology.
Kinch MS
Drug Discov Today; 2014 Dec; 19(12):1831-5. PubMed ID: 25172803
[TBL] [Abstract][Full Text] [Related]
2. 2022 in review: FDA approvals of new medicines.
Kinch MS; Kraft Z; Schwartz T
Drug Discov Today; 2023 Aug; 28(8):103622. PubMed ID: 37201782
[TBL] [Abstract][Full Text] [Related]
3. 2016 in review: FDA approvals of new molecular entities.
Griesenauer RH; Kinch MS
Drug Discov Today; 2017 Nov; 22(11):1593-1597. PubMed ID: 28687460
[TBL] [Abstract][Full Text] [Related]
4. 2023 in review: FDA approvals of new medicines.
Kinch MS; Kraft Z; Schwartz T
Drug Discov Today; 2024 May; 29(5):103966. PubMed ID: 38552777
[TBL] [Abstract][Full Text] [Related]
5. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
6. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
[TBL] [Abstract][Full Text] [Related]
7. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
8. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
[TBL] [Abstract][Full Text] [Related]
9. Oncology's trial and error: Analysis of the FDA withdrawn accelerated approvals.
Preziosi AJ; Priefer R
Life Sci; 2024 Jun; 346():122615. PubMed ID: 38582392
[TBL] [Abstract][Full Text] [Related]
10. A cross-sectional study of the FDA approved indications and supporting pivotal trials of small-molecular kinase inhibitors in cancer therapies with the biomarker of cancer driver gene.
Huang Y; Xiong W; Ma L; Wu H
Int J Cancer; 2022 Dec; 151(12):2107-2114. PubMed ID: 35860988
[TBL] [Abstract][Full Text] [Related]
11. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
[TBL] [Abstract][Full Text] [Related]
12. An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020.
Wang S; Yang Q; Deng L; Lei Q; Yang Y; Ma P; Men Y; Yung BC; Lee RJ; Zhang M; Li N
Drug Discov Today; 2022 May; 27(5):1236-1250. PubMed ID: 34971818
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
Darrow JJ; Avorn J; Kesselheim AS
JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
[TBL] [Abstract][Full Text] [Related]
14. The response rate of alternative treatments for drugs approved on the basis of response rate.
Haslam A; Gill J; Prasad V
Int J Cancer; 2021 Feb; 148(3):713-722. PubMed ID: 32700797
[TBL] [Abstract][Full Text] [Related]
15. Trends in the approval of cancer therapies by the FDA in the twenty-first century.
Scott EC; Baines AC; Gong Y; Moore R; Pamuk GE; Saber H; Subedee A; Thompson MD; Xiao W; Pazdur R; Rao VA; Schneider J; Beaver JA
Nat Rev Drug Discov; 2023 Aug; 22(8):625-640. PubMed ID: 37344568
[TBL] [Abstract][Full Text] [Related]
16. Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021.
Kandemir EA
J Oncol Pharm Pract; 2023 Jan; 29(1):191-207. PubMed ID: 35793068
[TBL] [Abstract][Full Text] [Related]
17. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
[TBL] [Abstract][Full Text] [Related]
18. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
[TBL] [Abstract][Full Text] [Related]
19. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
Chen EY; Raghunathan V; Prasad V
JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822
[TBL] [Abstract][Full Text] [Related]
20. Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.
Jacquet E; Kerouani-Lafaye G; Grude F; Goncalves S; Lorence A; Turcry F; Brunel L; Belgodere L; Monard A; Guyader G; Boudali L; Albin N
Eur J Cancer; 2021 May; 149():82-90. PubMed ID: 33838392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
